Sector News

Former Sanofi UK head joins Pertinax Pharma as chairman

November 22, 2017
Life sciences

UK-based Pertinax Pharma says that Nigel Brooksby, a former chairman of Sanofi UK, has been appointed as chairman of the company, where he will drive the commercialization of the company’s Pertinax.

His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialization phase following the launch last month of Pertinax, a slow-release technology that provides a continual release of chlorhexidine (CHX).

This unique technology which enablescontrolled and sustained release of the antimicrobial, chlorhexidine (CHX) has wide ranging potential applications, spanning the wound care, medical device, dental and veterinary markets. Pertinax Pharma – originally a spin out from the University of Bristol – was established in April 2015.

Until his retirement, Mr Brooksby was a member of the Sanofi executive committee in Europe and America and chairman and managing director of the Sanofi Group in the UK and Ireland.

Mr Brooksby is highly regarded as an experienced businessman and entrepreneur in the life sciences arena. Over the last seven years since his retirement from Sanofi, he has been involved as chairman, director and strategic adviser in raising significant investment. In his role as chairman of the UK Life Sciences Strategy Board, he secured a £32 million ($42 million) bid from the UK government for the continued expansion and development of skills for the life sciences sector. In 2015, he was instrumental in gaining a listing for a clinical stage biopharma company on NASDAQ, in which he continues to be a key investor and director. He is also a non-executive director at Porton Biopharma, a director of Stabilitech Pharma, and a non-executive director at Chronos Therapeutics. Mr Brooksby is also chairman of Clinical Insights Ltd and Neurocentrx Pharma.

Mr Brooksby commented: “I am delighted to take on this position at such a pivotal phase in the company’s development. Pertinax has enormous market potential in multiple fields. We are already in talks with several manufacturers and over the course of the next twelve months, we confidently expect to have applications of Pertinax in development for use in wound care, veterinary and dental products.”

Michele Barbour, founder and chief scientific officer of Pertinax Pharma, commented: “We are delighted that Nigel has chosen to join our board. His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand. Indeed, we look forward to Nigel playing a pivotal role in Pertinax Pharma’s continued development as we bring the benefits of our patented and commercialized Pertinax technology to the healthcare sector.”

Source: The Pharma Letter

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach